Alexis Borisy
CIK 1319446 · Executive Chairman · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$456.19M
Companies
12
Total Filings
71
Lifetime Open-Market Net
-$25.83M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RVMD | Director | 2,340,075 | $183.86 | $430.25M | $0 | 6 | 2026-06-23 |
| PBLS | Director | 105,414 | — | — | $0 | 2 | 2026-06-15 |
| RLAY | Director | 234,175 | $18.29 | $4.28M | $0 | 10 | 2026-06-10 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 74,160 | $129.46 | $9.60M | -$2.01M | 18 | 2025-07-21 |
| RVMDW | Director | 2,338,884 | $8.84 | $20.68M | $0 | 3 | 2025-06-30 |
| TNGX | Director | 17,500 | $26.65 | $466.4K | $0 | 4 | 2025-06-09 |
| EQRx, Inc. (EQRXW) Delisted | Executive Chairman | 0 | $0.05 | $0 | $0 | 3 | 2023-11-09 |
| OPK | Director | 312,612 | $1.65 | $515.8K | $0 | 4 | 2023-06-23 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Director | 256 | $11.19 | $2.9K | $0 | 5 | 2021-09-23 |
| Foundation Medicine, Inc. (FMI) Delisted | Director | 6,642,818 | — | — | -$23.82M | 7 | 2017-06-22 |
| EDIT | Director | 0 | $2.62 | $0 | $0 | 2 | 2017-06-19 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | CEO & President | 312,204 | — | — | -$3.3K | 6 | 2009-01-28 |
Recent Filings · Page 2 of 8
71 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-24 | RVMDW | Grant (A) | +4,800 | $0 | EDGAR |
| 2024-06-14 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +2,242 | $0 | EDGAR |
| 2024-06-07 | TNGX | Grant (A) | +6,250 | $0 | EDGAR |
| 2024-06-05 | RLAY | Grant (A) | — | $0 | EDGAR |
| 2023-11-14 | RVMD | Grant (A) | +2,091,672 | $0 | EDGAR |
| 2023-11-09 | EQRx, Inc. (EQRXW) Delisted | Disp (D) | −18,810,000 | $0 | EDGAR |
| 2023-06-23 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | +2,600 | $0 | EDGAR |
| 2023-06-23 | OPK | Grant (A) | — | $0 | EDGAR |
| 2023-06-12 | RVMD | Grant (A) | +5,200 | $0 | EDGAR |
| 2023-06-08 | TNGX | Grant (A) | +5,000 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.